ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2018, Vol. 10 ›› Issue (6): 528-531.doi: 10.3969/j.issn.1674-3865.2018.06.021

• 临床研究 • 上一篇    下一篇

ALL患儿经SCCLG2016方案治疗后复发的相关因素分析

刘仕林，文飞球，刘四喜，李长钢   

  1. 518038 广东 深圳，深圳市儿童医院血液肿瘤科
  • 出版日期:2018-12-25 发布日期:2019-03-25
  • 通讯作者: 文飞球，E-mail：meiyi1986my@163.com
  • 作者简介:刘仕林（1980-），男，医学硕士，主治医师。研究方向：儿童血液肿瘤性疾病的诊治
  • 基金资助:
    深圳市科创委项目（JCYJ20150403100317054）

Analysis of related factors for recurrence of ALL in child patients after treatment with SCCLG-2016 regimen

LIU Shilin, WEN Feiqiu, LIU Sixi, LI Changgang   

  1. Department of Hematology and Oncology, Shenzhen Children' s Hospital, Shenzhen 518038, China
  • Online:2018-12-25 Published:2019-03-25

PDF (PC)

134

摘要：
目的
分析急性淋巴细胞白血病（ALL）患儿经华南地区儿童急性淋巴细胞白血病治疗协作组2016方案（SCCLG-2016）治疗后复发的相关因素。
方法
选择2016年8月至2017年8月深圳市儿童医院血液肿瘤科收治ALL患儿364例为研究对象，分析364例接受SCCLG-2016方案治疗的结果，随访复发情况和相关病理资料，采用Logistics回归分析影响其治疗后复发的独立危险因素。
结果
364例ALL患儿复发率为18.68%（68/364），复发组与未复发组患儿年龄、白细胞数目、融合基因阳性率、微小残留病变及危险度分级比较差异均有统计学意义（P<0.05），其中年龄≥10岁、白细胞数目≥100×109/L和BCR/ABL基因阳性、危险分级为高危者是影响ALL患儿治疗后复发的独立危险因素。
结论
年龄≥10岁、白细胞数目≥100×109/L及融合基因阳性、危险分级为高危是ALL患儿经SCCLG-2016方案治疗后复发的独立危险因素，治疗时密切关注以上因素，有利于识别复发概率较高者，早期干预。

关键词: 急性淋巴细胞白血病, SCCLG-2016方案, 复发, 儿童

Abstract:
Objective
To analyze the related factors for recurrence acute lymphoblastic leukemia(ALL) in child patients after treatment with 2016 regimen of South China Children's Acute Lymphocytic Leukemia Treatment Cooperative Group(SCCLG-2016).
Methods
Totally 364 child patients with ALL who underwent SCCLG2016 regimen in Department of Hematology and Oncology of Shenzhen Children's Hospital were selected for the study. The treatment results of 364 patients who underwent SCCLG-2016 regimen were analyzed, and the recurrence and related pathological data were followed up. Logistics regression analysis was used to analyze the independent risk factors affecting recurrence after treatment.
Results
The recurrence rate was 18.68% (68/364) in 364 children patients with ALL, and there were significant differences in the age, white blood cell count, fusion gene positive rate, minimal residual disease and risk grading between recurrence group and no-recurrence group(P<0.05). The age ≥10 years old, white blood cell count ≥100×109/L and positive BCR/ABL gene and high risk grade were independent risk factors for recurrence in child patients with ALL after treatment.
ConclusionAge ≥10 years old, white blood cell count ≥100×109/L, positive fusion gene and high risk grade are independent risk factors for recurrence in child patients with ALL after SCCLG-2016 regimen. Paying close attention to the above factors during treatment is helpful to identify the patients with higher probability of recurrence so as to give early intervention.

Key words: Acute lymphoblastic leukemia, SCCLG-2016 regimen, Recurrence, Children